Premium
2seventy bio Inc (TSVT)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.
Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in...
2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants...
2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.24 | -7.61904761905 | 3.15 | 3.22 | 2.83 | 754496 | 2.91354071 | CS |
| 4 | -0.6 | -17.094017094 | 3.51 | 4.07 | 2.78 | 405549 | 3.12198671 | CS |
| 12 | -1.9 | -39.501039501 | 4.81 | 5.3 | 2.78 | 332568 | 3.89966095 | CS |
| 26 | -0.98 | -25.1928020566 | 3.89 | 5.3 | 2.78 | 348005 | 4.25765137 | CS |
| 52 | -1.19 | -29.0243902439 | 4.1 | 6.4 | 2.78 | 696854 | 4.5652216 | CS |
| 156 | -22.68 | -88.6283704572 | 25.59 | 27.04 | 1.535 | 800806 | 7.36213808 | CS |
| 260 | -23.22 | -88.8633754305 | 26.13 | 44.34 | 1.535 | 787944 | 8.19234966 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
